The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Research

• Publication date

  2009-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/0008-5472.CAN-08-3933PMID 19244106
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of CYP2D6*10 on recurrence‐free survival in breast cancer patients receiving adjuvant tamoxifen therapy

  2008cited by this paper
• Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

  2008cited by this paper
• New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

  2007cited by this paper
• Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.

  2007cited by this paper
• Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen.

  2007cited by this paper
• Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.

  2007cited by this paper
• Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

  2007cited by this paper
• Estrogen receptor α/β isoforms, but not βcx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells

  2007cited by this paper
• The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

  2006cited by this paper
• Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

  2006cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

  2005cited by this paper
• The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. 1992.

  2004cited by this paper
• Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

  2004cited by this paper
• Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  2004cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper
• Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta.

  2003cited by this paper
• Estrogen receptor isoform‐specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERα or ERβ

  2003cited by this paper
• Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen.

  2003cited by this paper
• Mutual antagonism of estrogen receptors alpha and beta and their preferred interactions with steroid receptor coactivators in human osteoblastic cell lines.

  2003cited by this paper
• The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

  1992cited by this paper

• Mono-CYP CHO Model: A Recombinant Chinese Hamster Ovary Cell Platform for Investigating CYP-Specific Tamoxifen Metabolism

  2025cites this paper
• The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen

  2025cites this paper
• Evaluation of a targeted next-generation sequencing-based CYP2D6 genotyping method compared with Sanger sequencing and multiplex ligation-dependent probe amplification.

  2025cites this paper
• Validation of an Estrogen Receptor Dimerization(α-α/α-β/β-β) BRET-Based Biosensors for Screening Estrogenic Endocrine-Disrupting Chemicals.

  2025cites this paper
• Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis.

  2025cites this paper
• Prolonged Low-Dose Administration of FDA-Approved Drugs for Non-Cancer Conditions: A Review of Potential Targets in Cancer Cells

  2025cites this paper
• Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data

  2024cites this paper
• Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies.

  2024cites this paper
• A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects.

  2024cites this paper
• Potential of covalently linked tamoxifen hybrids for cancer treatment: recent update.

  2024cites this paper
• Resveratrol Analogs and Prodrugs Differently Affect the Survival of Breast Cancer Cells Impairing Estrogen/Estrogen Receptor α/Neuroglobin Pathway

  2023cites this paper
• Enhancing Solid-Phase Extraction of Tamoxifen and Its Metabolites from Human Plasma Using MOF-Integrated Polyacrylonitrile Composites: A Study on CuBTC and ZIF-8 Efficacy

  2023cites this paper
• Stereoselective Synthesis of Silylated Vinylboronates by a Boron-Wittig Reaction and Their Application to Tetrasubstituted Olefins.

  2023cites this paper
• ANTICANCER ACTIVITY OF VITAMIN D3–TAMOXIFEN COMBINATION MICROEMULSION ON MCF-7 BREAST CELL LINE AND ITS SYNERGISTIC EFFECT

  2023cites this paper
• Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

  2023cites this paper
• CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.

  2023cites this paper
• Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer.

  2023cites this paper
• Inhibition of Cytochrome P450s by Strobilanthes crispus Sub-Fraction (F3): Implication for Herb–Drug Interaction

  2022cites this paper
• Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors

  2022cites this paper
• Challenging Approach to the Development of Novel Estrogen Receptor Modulators Based on the Chemical Properties of Guaiazulene

  2022cites this paper
• Molecular Docking and in silico Pharmacological Screening of Oleosin from Cocos Nucifera Complexed with Tamoxifen in Developing Potential Breast Chemotherapeutic Leads

  2022cites this paper
• Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism

  2022influential citation
• Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism

  2022influential citation
• Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism

  2022influential citation
• Impact of Irradiation on the Pharmacokinetics and Biotransformation of Tamoxifen

  2022cites this paper
• Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism

  2022influential citation
• New steps on an old path: Novel estrogen receptor inhibitors in breast cancer.

  2022cites this paper
• Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies

  2022cites this paper
• Endoxifen, an Estrogen Receptor Targeted Therapy: from Bench to Bedside.

  2021cites this paper
• Fungi for the bioremediation of pharmaceutical-derived pollutants: A bioengineering approach to water treatment

  2021cites this paper
• p21 activated kinase-1 and tamoxifen - A deadly nexus impacting breast cancer outcomes.

  2021cites this paper
• Single-cell immunoblotting resolves estrogen receptor-α isoforms in breast cancer

  2021cites this paper
• Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer

  2021cites this paper
• Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial

  2021cites this paper
• Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

  2021cites this paper
• CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Drug Response: A Secondary Analyses of the KARISMA Trial.

  2021cites this paper
• Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models

  2021cites this paper
• Recent Advances in the Synthesis of Tamoxifen and Analogues in Medicinal Chemistry

  2020cites this paper
• Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics

  2020cites this paper
• Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

  2020cites this paper
• Norlichexanthone purified from plant endophyte prevents postmenopausal osteoporosis by targeting ERα to inhibit RANKL signaling

  2020cites this paper
• Prescribing for Women with Breast Cancer in Their Survivorship Phase for Menopausal Symptoms.

  2020cites this paper
• Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro

  2019cites this paper
• Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer

  2019cites this paper
• Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen

  2019cites this paper
• Localized Transdermal Delivery of Chemopreventive Agents to the Breast

  2019cites this paper
• Impact of CYP2D6 polymorphisms on tamoxifen treatment in patients with retroperitoneal fibrosis: A first step towards tailored therapy?

  2019cites this paper
• HDAC2 and PCNA expression is correlated to decreasing of endoxifen sensitivity in human breast cancer stem cells ALDH+

  2019cites this paper
• Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives.

  2018cites this paper
• CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines

  2018cites this paper
• Potentiation of paclitaxel effect by resveratrol in human breast cancer cells by counteracting the 17β‐estradiol/estrogen receptor α/neuroglobin pathway

  2018cites this paper
• The development of endoxifen for breast cancer.

  2018cites this paper
• Curcumin for the Prevention of Epithelial-Mesenchymal Transition in Endoxifen-Treated MCF-7 Breast Cancer Cells

  2018cites this paper
• Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy.

  2018cites this paper
• Exploring the Regulatory Mechanism of the Notch Ligand Receptor Jagged1 Via the Aryl Hydrocarbon Receptor in Breast Cancer

  2018cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

  2018cites this paper
• Personalized Medicine in Cancer Treatment

  2017cites this paper
• Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels

  2017cites this paper
• Advances and challenges in hereditary cancer pharmacogenetics

  2017cites this paper
• Structural modeling for DNA and RNA bindings to breast anticancer drug tamoxifen and its metabolites

  2017cites this paper
• Skeletal and Uterotrophic Effects of Endoxifen in Female Rats

  2017cites this paper
• Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation

  2017cites this paper
• Potential of amphiphilic graft copolymer &agr;‐tocopherol succinate‐g‐carboxymethyl chitosan in modulating the permeability and anticancer efficacy of tamoxifen

  2017cites this paper
• High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer

  2017cites this paper
• The activation of the G protein-coupled estrogen receptor (GPER) inhibits the proliferation of mouse melanoma K1735-M2 cells.

  2017cites this paper
• Significance of CYP2D Polymorphism

  2017cites this paper
• Elucidation of the Molecular Mechanisms Underlying Estrogen-Mediated Estrogen Receptor Activation

  2017cites this paper
• Increased vimentin mRNA expression in MCF-7 breast cancer cell line after repeated endoxifen-treatment

  2017cites this paper
• First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

  2017cites this paper
• Targeted LC–MS Quantification of Androgens and Estrogens for Biomarker Development

  2017cites this paper
• Are plasma concentrations of tamoxifen active metabolites sufficient to ensure therapeutic efficacy for tamoxifen treated women with breast cancer in Poland

  2016cites this paper
• Tamoxifen promotes differentiation of oligodendrocyte progenitors in vitro.

  2016cites this paper
• Novel routes for administering chemoprevention: local transdermal therapy to the breasts.

  2016cites this paper
• Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections

  2016cites this paper
• A Way Forward for Cancer Chemoprevention: Think Local

  2016cites this paper
• Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

  2016cites this paper
• Tamoxifen metabolite endoxifen interferes with the polyamine pathway in breast cancer

  2016cites this paper
• Investigation into the human premature ageing disease, Hutchinson Gilford Progeria syndrome, using hTERT immortalised fibroblasts

  2016cites this paper
• Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold

  2016cites this paper
• Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.

  2016cites this paper
• Pharmacogenomics of Breast Cancer

  2016cites this paper
• Tamoxifen Pharmacokinetics Beyond the Genotyping Era

  2015cites this paper
• Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen

  2015cites this paper
• Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer

  2015cites this paper
• Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer

  2015cites this paper
• Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.

  2015cites this paper
• Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

  2015cites this paper
• Reciprocal Regulation of ERα and ERβ Stability and Activity by Diptoindonesin G.

  2015cites this paper
• CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

  2015cites this paper
• Determination of tamoxifen and its metabolites in human plasma by nonaqueous capillary electrophoresis with contactless conductivity detection

  2015cites this paper
• Current medical treatment of estrogen receptor-positive breast cancer.

  2015cites this paper
• Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

  2015cites this paper
• The Effects of Endoxifen and Other Major Metabolites of Tamoxifen on the Sulfation of Estradiol Catalyzed by Human Cytosolic Sulfotransferases hSULT1E1 and hSULT1A1*1

  2015cites this paper
• Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study.

  2015cites this paper
• Rethinking tamoxifen in the management of melanoma: New answers for an old question.

  2015cites this paper
• Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4-Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells

  2014cites this paper
• Emerging strategies to overcome resistance to endocrine therapy for breast cancer

  2014influential citation
• Bioanalysis and clinical pharmacology of tamoxifen in breast cancer

  2014cites this paper
• Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling

  2014cites this paper
• The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton

  2014cites this paper